Compare Kohl's Corporation (KSS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs BIO-TECHNE Corp — how do they compare? Kohl's Corporation trades at $18.61 (market cap $2.16B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 5.2× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| KSS | TECH | |
|---|---|---|
Market Cap | $2.16B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $72.29 |
52-Week Low | $11.72 | $43.31 |
Enterprise Value | $8.26B | $11.32B |
Dividend Yield | 2.63% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $19.30, up 4.54% in the last session, with a bullish technical signal from moving averages. The stock shows attractive valuation ratios, including a P/E of 8.11 and P/B of 0.54, but faces revenue declines from $16.22B in 2025 to an expected $15.5B in 2026. Recent Q1 2026 earnings beat estimates, and the company appointed a new COO to drive operational improvements.
The outlook is mixed: low valuations and earnings beats offer upside, but persistent sales drops and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
